- Overview
- 150 Years
- News
- Biographies
- Speeches
- Photos
- TV Footage
- Publications
- Video Center
- Social Media Channels
- Apps
- Events
- Stories
- Media Contact
News
Wednesday - June 19, 2013Expansion of a global Wheat Breeding Network:
Bayer CropScience opens Wheat Breeding Station in Milly-la-Forêt near Paris, France
Breeding program focuses on increasing yields, addressing environmental challenges and improving wheat varieties / Investment of more than EUR 7 million over three years in site facilities / Rebuilding will double capacity of laboratory and greenhouse more
Monday - June 17, 2013Anniversary Song Project
150 Years of Bayer: pop song for a good cause
Employee teams from various countries record "A Better Life" more
Wednesday - June 12, 2013Commercial launch of technology from Bayer and ThyssenKrupp:
Chlorine production with much less electricity
New process reduces energy consumption by roughly one-third / Trial phase completed successfully more
SPECIALIZED PRESS
Diabetes Care:
Bayer HealthCare supports diabetes projects in the Middle East, North Africa and Europe
“Excellence across Borders” program fosters practical solutions in diabetes management to propel therapy outcome more
SPECIALIZED PRESS
High-class outfit of car seats, sports and fashion goods
Bayer develops solvent-free raw materials for textile coating
Polyurethane dispersions fulfill the highest requirements more
Thursday - June 6, 2013
Not intended for U.S. and UK Media - VEGF Trap-Eye in myopic choroidal neovascularization:
Positive Phase 3 Results for VEGF Trap-Eye (Intravitreal Aflibercept) in Myopic Choroidal Neovascularization (mCNV) more
Not intended for U.S. and UK Media - VEGF Trap-Eye in myopic choroidal neovascularization:
Positive Phase 3 Results for VEGF Trap-Eye (Intravitreal Aflibercept) in Myopic Choroidal Neovascularization (mCNV) more
Wednesday - June 5, 2013
Bayer Science & Education Foundation launches new round of funding:
Bayer foundation scholarships – EUR 200,000 for work and study abroad
Support for ambitious study projects in the fields of science, engineering, medicine and teacher training in scientific subjects / Hermann Strenger scholarships to sponsor career-training projects abroad / Applications now possible online till July 15, 2013 more
Bayer Science & Education Foundation launches new round of funding:
Bayer foundation scholarships – EUR 200,000 for work and study abroad
Support for ambitious study projects in the fields of science, engineering, medicine and teacher training in scientific subjects / Hermann Strenger scholarships to sponsor career-training projects abroad / Applications now possible online till July 15, 2013 more
Wednesday - June 5, 2013
Tender offer successful:
Bayer acquires majority interest in Conceptus
96.4 percent of Conceptus’ shares tendered / Conceptus imminently to become a wholly-owned Bayer subsidiary more
Tender offer successful:
Bayer acquires majority interest in Conceptus
96.4 percent of Conceptus’ shares tendered / Conceptus imminently to become a wholly-owned Bayer subsidiary more
Sunday - June 2, 2013
Not intended for U.S. and UK Media - Results of pivotal Phase III study in differentiated thyroid cancer:
Positive Phase III Data on Sorafenib Show Significant Improvement in Progression-Free Survival Time in Patients with Radioactive Iodine Refractory Differentiated Thyroid Cancer
Currently there are no approved therapies specifically for radioactive iodine refractory differentiated thyroid cancer / Sorafenib (Nexavar®) significantly extended progression-free survival; median progression-free survival of 10.8 months, compared to 5.8 months with placebo / Results from pivotal Phase III DECISION trial presented in plenary session at Annual Meeting of the American Society of Clinical Oncology more
Not intended for U.S. and UK Media - Results of pivotal Phase III study in differentiated thyroid cancer:
Positive Phase III Data on Sorafenib Show Significant Improvement in Progression-Free Survival Time in Patients with Radioactive Iodine Refractory Differentiated Thyroid Cancer
Currently there are no approved therapies specifically for radioactive iodine refractory differentiated thyroid cancer / Sorafenib (Nexavar®) significantly extended progression-free survival; median progression-free survival of 10.8 months, compared to 5.8 months with placebo / Results from pivotal Phase III DECISION trial presented in plenary session at Annual Meeting of the American Society of Clinical Oncology more
Publications
Events
Wednesday, July 31, 2013
Q2 2013 Interim Report
Additional Press Events
Investor Relations Events
BayKomm Events
Q2 2013 Interim Report
